Clinical Trial Update: Lamivudine and Plasma Markers of Inflammation in Retinal Detachment [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating lamivudine for inflammatory plasma markers in rhegmatogenous retinal detachment was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Detachment
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Lamivudine (lamivudine)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Retinal Detachment, Rhegmatogenous Retinal Detachment | EARLY_Phase 1 | Status: TERMINATED